Manuel Salto-Tellez

List of Publications by Citations

108	4,042	28	62
papers	citations	h-index	g-index

127	6,065	6.9	5.41
ext. papers	ext. citations	avg, IF	L-index

#	Paper	IF	Citations
108	QuPath: Open source software for digital pathology image analysis. *Scientific Reports*, **2017**, 7, 16878	4.9	1369
107	Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer. *Journal of the National Cancer Institute*, **2017**, 109,	9.7	211
106	Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer. *Modern Pathology*, **2003**, 16, 79-84	9.8	146
105	Digital pathology and image analysis in tissue biomarker research. *Methods*, **2014**, 70, 59-73	4.6	120
104	Identification of a BRCA1-mRNA splicing complex required for efficient DNA repair and maintenance of genomic stability. *Molecular Cell*, **2014**, 54, 445-59	17.6	116
103	Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges. *Nature Reviews Clinical Oncology*, **2017**, 14, 562-576	19.4	102
102	Challenging the Cancer Molecular Stratification Dogma: Intratumoral Heterogeneity Undermines Consensus Molecular Subtypes and Potential Diagnostic Value in Colorectal Cancer. *Clinical Cancer Research*, **2016**, 22, 4095-104	12.9	88
101	AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer. *Clinical Cancer Research*, **2014**, 20, 164-75	12.9	83
100	MicroRNA-34c inversely couples the biological functions of the runt-related transcription factor RUNX2 and the tumor suppressor p53 in osteosarcoma. *Journal of Biological Chemistry*, **2013**, 288, 21307-21319	5.4	82
99	EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer. *Clinical Cancer Research*, **2016**, 22, 230-242	12.9	73
98	Identification and validation of an anthracycline/cyclophosphamide-based chemotherapy response assay in breast cancer. *Journal of the National Cancer Institute*, **2014**, 106, djt335	9.7	73
97	BRCA1 deficiency exacerbates estrogen-induced DNA damage and genomic instability. *Cancer Research*, **2014**, 74, 2773-2784	10.1	69
96	Elucidating the molecular physiopathology of acute respiratory distress syndrome in severe acute respiratory syndrome patients. *Virus Research*, **2009**, 145, 260-9	6.4	66
95	Artificial intelligence-the third revolution in pathology. *Histopathology*, **2019**, 74, 372-376	7.3	61
94	Next-generation sequencing: a change of paradigm in molecular diagnostic validation. *Journal of Pathology*, **2014**, 234, 5-10	9.4	58
93	The prognostic significance of the aberrant extremes of p53 immunophenotypes in breast cancer. *Histopathology*, **2014**, 65, 340-52	7.3	54
92	Guidelines and considerations for conducting experiments using tissue microarrays. *Histopathology*, **2013**, 62, 827-39	7.3	50

91	Integrated tumor identification and automated scoring minimizes pathologist involvement and provides new insights to key biomarkers in breast cancer. *Laboratory Investigation*, **2018**, 98, 15-26	5.9	47
90	Evaluation of PTGS2 Expression, PIK3CA Mutation, Aspirin Use and Colon Cancer Survival in a Population-Based Cohort Study. *Clinical and Translational Gastroenterology*, **2017**, 8, e91	4.2	42
89	Tissue-based next generation sequencing: application in a universal healthcare system. *British Journal of Cancer*, **2017**, 116, 553-560	8.7	31
88	Comprehensive molecular pathology analysis of small bowel adenocarcinoma reveals novel targets with potential for clinical utility. *Oncotarget*, **2015**, 6, 20863-74	3.3	31
87	Immune-Derived PD-L1 Gene Expression Defines a Subgroup of Stage II/III Colorectal Cancer Patients with Favorable Prognosis Who May Be Harmed by Adjuvant Chemotherapy. *Cancer Immunology Research*, **2016**, 4, 582-91	12.5	31
86	Epidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancer. *Journal of Translational Medicine*, **2015**, 13, 217	8.5	30
85	Automated tumor analysis for molecular profiling in lung cancer. *Oncotarget*, **2015**, 6, 27938-52	3.3	30
84	Immunohistochemistry in the era of personalised medicine. *Journal of Clinical Pathology*, **2013**, 66, 58-61	3.9	30
83	Recommendations for determining HPV status in patients with oropharyngeal cancers under TNM8 guidelines: a two-tier approach. *British Journal of Cancer*, **2019**, 120, 827-833	8.7	29
82	Sphingosine kinase 1 promotes malignant progression in colon cancer and independently predicts survival of patients with colon cancer by competing risk approach in South asian population. *Clinical and Translational Gastroenterology*, **2014**, 5, e51	4.2	29
81	Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis. *Cancer Discovery*, **2021**, 11, 1212-1227	24.4	29
80	Immunohistochemistry should undergo robust validation equivalent to that of molecular diagnostics. *Journal of Clinical Pathology*, **2015**, 68, 766-70	3.9	28
79	Digital pathology and artificial intelligence will be key to supporting clinical and academic cellular pathology through COVID-19 and future crises: the PathLAKE consortium perspective. *Journal of Clinical Pathology*, **2021**, 74, 443-447	3.9	28
78	BCL-2 system analysis identifies high-risk colorectal cancer patients. *Gut*, **2017**, 66, 2141-2148	19.2	27
77	Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies. *British Journal of Cancer*, **2017**, 117, 203-209	8.7	27
76	Validation of the systematic scoring of immunohistochemically stained tumour tissue microarrays using QuPath digital image analysis. *Histopathology*, **2018**, 73, 327-338	7.3	27
75	Molecular pathology - the value of an integrative approach. *Molecular Oncology*, **2014**, 8, 1163-8	7.9	27
74	Critical Appraisal of Programmed Death Ligand 1 Reflex Diagnostic Testing: Current Standards and Future Opportunities. *Journal of Thoracic Oncology*, **2019**, 14, 45-53	8.9	27

73	Statin use, candidate mevalonate pathway biomarkers, and colon cancer survival in a population-based cohort study. *British Journal of Cancer*, **2017**, 116, 1652-1659	8.7	26
72	A robust multiplex immunofluorescence and digital pathology workflow for the characterisation of the tumour immune microenvironment. *Molecular Oncology*, **2020**, 14, 2384-2402	7.9	26
71	Quantification of HER2 heterogeneity in breast cancer-implications for identification of sub-dominant clones for personalised treatment. *Scientific Reports*, **2016**, 6, 23383	4.9	26
70	Building a QRepository of ScienceQThe importance of Integrating biobanks within molecular pathology programmes. *European Journal of Cancer*, **2016**, 67, 191-199	7.5	26
69	Analysis of wntless (WLS) expression in gastric, ovarian, and breast cancers reveals a strong association with HER2 overexpression. *Modern Pathology*, **2015**, 28, 428-36	9.8	25
68	PTEN deficiency promotes macrophage infiltration and hypersensitivity of prostate cancer to IAP antagonist/radiation combination therapy. *Oncotarget*, **2016**, 7, 7885-98	3.3	25
67	Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer. *Journal of Oncology*, **2018**, 2018, 2937012	4.5	25
66	RNAscope hybridization confirms mRNA integrity in formalin-fixed, paraffin-embedded cancer tissue samples. *Oncotarget*, **2017**, 8, 93392-93403	3.3	24
65	Immune status is prognostic for poor survival in colorectal cancer patients and is associated with tumour hypoxia. *British Journal of Cancer*, **2020**, 123, 1280-1288	8.7	22
64	Improving the Diagnostic Accuracy of the PD-L1 Test with Image Analysis and Multiplex Hybridization. *Cancers*, **2020**, 12,	6.6	20
63	Invited review-next-generation sequencing: a modern tool in cytopathology. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2019**, 475, 3-11	5.1	18
62	Time for change: a new training programme for morpho-molecular pathologists?. *Journal of Clinical Pathology*, **2018**, 71, 285-290	3.9	16
61	Natural killer-like signature observed post therapy in locally advanced rectal cancer is a determinant of pathological response and improved survival. *Modern Pathology*, **2017**, 30, 1287-1298	9.8	14
60	A Stepwise Integrated Approach to Personalized Risk Predictions in Stage III Colorectal Cancer. *Clinical Cancer Research*, **2017**, 23, 1200-1212	12.9	14
59	The prognostic value of the stem-like group in colorectal cancer using a panel of immunohistochemistry markers. *Oncotarget*, **2015**, 6, 12763-73	3.3	14
58	Validation of immunocytochemistry as a morphomolecular technique. *Cancer Cytopathology*, **2016**, 124, 540-5	3.9	14
57	Identifying mismatch repair-deficient colon cancer: near-perfect concordance between immunohistochemistry and microsatellite instability testing in a large, population-based series. *Histopathology*, **2021**, 78, 401-413	7.3	14
56	Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma. *Gut*, **2019**, 68, 1918-1927	19.2	13

55	PICan: An integromics framework for dynamic cancer biomarker discovery. *Molecular Oncology*, **2015**, 9, 1234-40	7.9	13
54	Gastrointestinal tissue-based molecular biomarkers: a practical categorisation based on the 2019 World Health Organization classification of epithelial digestive tumours. *Histopathology*, **2020**, 77, 340-350	7.3	13
53	PTEN mRNA detection by chromogenic, RNA in situ technologies: a reliable alternative to PTEN immunohistochemistry. *Human Pathology*, **2016**, 47, 95-103	3.7	13
52	Standardising RNA profiling based biomarker application in cancer-The need for robust control of technical variables. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2017**, 1868, 258-272	11.2	12
51	The adaptive immune and immune checkpoint landscape of neoadjuvant treated esophageal adenocarcinoma using digital pathology quantitation. *BMC Cancer*, **2020**, 20, 500	4.8	12
50	Molecular pathology in contemporary diagnostic pathology laboratory: an opinion for the active role of surgical pathologists. *American Journal of Surgical Pathology*, **2010**, 34, 115-7	6.7	12
49	Glucose transporter 1 expression as a marker of prognosis in oesophageal adenocarcinoma. *Oncotarget*, **2018**, 9, 18518-18528	3.3	12
48	HER2 testing of gastro-oesophageal adenocarcinoma: a commentary and guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Committee. *Journal of Clinical Pathology*, **2018**, 71, 388-394	3.9	11
47	More Than a Decade of Molecular Diagnostic Cytopathology Leading Diagnostic and Therapeutic Decision-Making. *Archives of Pathology and Laboratory Medicine*, **2018**, 142, 443-445	5	11
46	Stratified analysis reveals chemokine-like factor (CKLF) as a potential prognostic marker in the MSI-immune consensus molecular subtype CMS1 of colorectal cancer. *Oncotarget*, **2016**, 7, 36632-36644	3.3	10
45	Diagnosis of digestive system tumours. *International Journal of Cancer*, **2021**, 148, 1040-1050	7.5	10
44	Comparison of Molecular Assays for HPV Testing in Oropharyngeal Squamous Cell Carcinomas: A Population-Based Study in Northern Ireland. *Cancer Epidemiology Biomarkers and Prevention*, **2020**, 29, 31-38	4	9
43	Severity of gastric intestinal metaplasia predicts the risk of gastric cancer: a prospective multicentre cohort study (GCEP). *Gut*, **2021**,	19.2	9
42	Defining the molecular evolution of extrauterine high grade serous carcinoma. *Gynecologic Oncology*, **2019**, 155, 305-317	4.9	8
41	Gelsolin-mediated activation of PI3K/Akt pathway is crucial for hepatocyte growth factor-induced cell scattering in gastric carcinoma. *Oncotarget*, **2016**, 7, 25391-407	3.3	8
40	QuPath: Open source software for digital pathology image analysis		8
39	QuPath: The global impact of an open source digital pathology system. *Computational and Structural Biotechnology Journal*, **2021**, 19, 852-859	6.8	8
38	A gene signature associated with PTEN activation defines good prognosis intermediate risk prostate cancer cases. *Journal of Pathology: Clinical Research*, **2018**, 4, 103-113	5.3	7

37	samExploreR: exploring reproducibility and robustness of RNA-seq results based on SAM files. *Bioinformatics*, **2016**, 32, 3345-3347	7.2	7
36	p16 as a prognostic indicator in ovarian/tubal high-grade serous carcinoma. *Histopathology*, **2016**, 68, 615-8	7.3	7
35	A Means of Assessing Deep Learning-Based Detection of ICOS Protein Expression in Colon Cancer. *Cancers*, **2021**, 13,	6.6	7
34	Training and accreditation standards for pathologists undertaking clinical trial work. *Journal of Pathology: Clinical Research*, **2019**, 5, 100-107	5.3	6
33	GLOBAL BALLAD: An International Rare Cancers Initiative trial to evaluate the potential benefit of adjuvant chemotherapy for small bowel adenocarcinoma (IRCI 002).. *Journal of Clinical Oncology*, **2016**, 34, TPS4154-TPS4154	2.2	6
32	Molecular classification of non-invasive breast lesions for personalised therapy and chemoprevention. *Oncotarget*, **2015**, 6, 43244-54	3.3	6
31	Low-contact and high-interconnectivity pathology (LC&HI Path): post-COVID19-pandemic practice of pathology. *Histopathology*, **2020**, 77, 518-524	7.3	5
30	Integrated molecular pathology: the Belfast model. *Drug Discovery Today*, **2015**, 20, 1451-4	8.8	5
29	Sex hormone receptor expression and survival in esophageal adenocarcinoma: a prospective cohort study. *Oncotarget*, **2018**, 9, 35300-35312	3.3	4
28	Alcohol intake, tobacco smoking, and esophageal adenocarcinoma survival: a molecular pathology epidemiology cohort study. *Cancer Causes and Control*, **2020**, 31, 1-11	2.8	4
27	Association of a DNA damage response deficiency (DDRD) assay and prognosis in early-stage esophageal adenocarcinoma.. *Journal of Clinical Oncology*, **2014**, 32, 4015-4015	2.2	3
26	MErCuRIC1: A Phase I study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in RASMT and RASWT (with aberrant c-MET) metastatic colorectal cancer (mCRC) patients.. *Journal of Clinical Oncology*, **2015**, 33, TPS3632-TPS3632	2.2	3
25	PD-L1 Multiplex and Quantitative Image Analysis for Molecular Diagnostics. *Cancers*, **2020**, 13,	6.6	3
24	Systematic evaluation of PAXgene tissue fixation for the histopathological and molecular study of lung cancer. *Journal of Pathology: Clinical Research*, **2020**, 6, 40-54	5.3	3
23	Evolutionary genetic algorithm identifies as a potential predictive biomarker for immune-checkpoint therapy in colorectal cancer. *NAR Genomics and Bioinformatics*, **2021**, 3, lqab016	3.7	3
22	The clinical and molecular significance associated with STING signaling in breast cancer. *Npj Breast Cancer*, **2021**, 7, 81	7.8	3
21	Delivering a research-enabled multistakeholder partnership for enhanced patient care at a population level: The Northern Ireland Comprehensive Cancer Program. *Cancer*, **2016**, 122, 664-73	6.4	3
20	Practical guide for the comparison of two next-generation sequencing systems for solid tumour analysis in a universal healthcare system. *Journal of Clinical Pathology*, **2019**, 72, 225-231	3.9	3

19	Impact of Variable RNA-Sequencing Depth on Gene Expression Signatures and Target Compound Robustness: Case Study Examining Brain Tumor (Glioma) Disease Progression. *JCO Precision Oncology*, **2018**, 2,	3.6	3
18	Swarm learning for decentralized artificial intelligence in cancer histopathology.. *Nature Medicine*, **2022**,	50.5	3
17	EORTC-1203: Integration of trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy (CT) of HER-2 positive stomach cancer INNOVATION trial.. *Journal of Clinical Oncology*, **2016**, 34, TPS4133-TPS4133	2.2	2
16	Vitamin D receptor as a marker of prognosis in oesophageal adenocarcinoma: a prospective cohort study. *Oncotarget*, **2018**, 9, 34347-34356	3.3	2
15	Colonic epithelial cathelicidin (LL-37) expression intensity is associated with progression of colorectal cancer and presence of CD8 T cell infiltrate. *Journal of Pathology: Clinical Research*, **2021**, 7, 495-506	5.3	2
14	Orthogonal MET analysis in a population-representative stage II-III colon cancer cohort: prognostic and potential therapeutic implications. *Molecular Oncology*, **2021**, 15, 3317-3328	7.9	2
13	NUQA: Estimating Cancer Spatial and Temporal Heterogeneity and Evolution through Alignment-Free Methods. *Molecular Biology and Evolution*, **2019**, 36, 2883-2889	8.3	1
12	In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer. *Clinical Cancer Research*, **2021**, 27, 288-300	12.9	1
11	HistoClean: Open-source software for histological image pre-processing and augmentation to improve development of robust convolutional neural networks. *Computational and Structural Biotechnology Journal*, **2021**, 19, 4840-4853	6.8	1
10	High PTGS2 expression in post-neoadjuvant chemotherapy-treated oesophageal adenocarcinoma is associated with improved survival: a population-based cohort study. *Histopathology*, **2019**, 74, 587-596	7.3	0
9	Re: test of four colon cancer risk-scores in formalin fixed paraffin embedded microarray gene expression data. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	
8	A digital pathology demonstration of an "immune hot" ICOS+/CD45RO+ immunephenotype and the impact on survival in patients with esophageal adenocarcinoma.. *Journal of Clinical Oncology*, **2019**, 37, 4062-4062	2.2	
7	The prognostic and therapeutic value of EpHA2 in early colorectal cancer (CRC).. *Journal of Clinical Oncology*, **2014**, 32, 3581-3581	2.2	
6	Molecular classification of the invasive front in colorectal cancer.. *Journal of Clinical Oncology*, **2015**, 33, 3573-3573	2.2	
5	Caspase modelling to predict personalised risk in stage III colorectal cancer (CRC) patients.. *Journal of Clinical Oncology*, **2016**, 34, 11592-11592	2.2	
4	A systems model of BCL-2 dependent apoptosis to predict stage II CRC patients benefiting from adjuvant chemotherapy and as a prognostic tool for stage III CRC patients with increased risk of recurrence.. *Journal of Clinical Oncology*, **2016**, 34, 3584-3584	2.2	
3	PD-L1 expression and response to neo-adjuvant chemotherapy in esophageal adenocarcinoma.. *Journal of Clinical Oncology*, **2017**, 35, 4023-4023	2.2	
2	Identification and validation of an assay predictive of response and prognosis following anthracycline-based chemotherapy for early breast cancer.. *Journal of Clinical Oncology*, **2013**, 31, TPS11120-TPS11120	2.2	

1 General Roadmap and Core Steps for the Development of AI Tools in Digital Pathology. *Diagnostics*, **2022**, 12, 1272 3.8